Assembly Biosciences, Inc.
ASMBNASDAQHealthcare● Active
$23.60
+$1.04(+4.63%)
Market Cap$375056571
P/E Ratio—
52W High$39.71
52W Low$15.71
Assembly Biosciences, Inc. (ASMB) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ASMB · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($6.12M) | ($40.18M) | ($61.23M) | ($93.09M) | ($129.85M) |
| Depreciation & Amort. | $0.13M | $0.13M | $0.45M | $0.50M | $0.47M |
| Stock-Based Comp. | $4.68M | $3.12M | $5.12M | $6.59M | $5.24M |
| Change in Working Capital | ($38.28M) | ($11.95M) | $76.34M | ($2.12M) | ($11.40M) |
| Net Cash from Operations | ($41.09M) | ($51.12M) | $22.74M | ($84.46M) | ($93.40M) |
| Investing Activities | |||||
| Capital Expenditure | ($0.07M) | ($0.03M) | ($0.26M) | ($0.10M) | ($3.10M) |
| Purchases of Investments | ($232.18M) | ($90.50M) | ($133.92M) | ($27.58M) | ($160.45M) |
| Sales of Investments | $116.43M | $130.70M | $65.02M | $116.83M | $187.70M |
| Net Cash from Investing | ($113.47M) | $40.17M | ($69.14M) | $90.64M | $26.52M |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Financing | $174.67M | $29.45M | $13.82M | $0.61M | $53.06M |
| Free Cash Flow | |||||
| Free Cash Flow | ($41.16M) | ($51.15M) | $22.49M | ($84.56M) | ($96.49M) |
| FCF Margin %(computed) | -56.93% | -179.33% | 313.95% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Assembly Biosciences, Inc. data
About Assembly Biosciences, Inc. (ASMB) Cash Flow Statement
Assembly Biosciences, Inc. generated operating cash flow of ($0.04B) and free cash flow of ($0.04B) for 2025 — a FCF margin of -56.93%. Capital expenditure was ($0.00B).
Frequently asked questions
ASMB · 4 questionsAssembly Biosciences, Inc. generated free cash flow of ($0.04B) for 2025, up 19.5% year-over-year.
ASMB free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10